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Abstract
Cancer is a disease of multicellular animals caused by unregulated cell division.
The prevailing model of cancer (multistage carcinogenesis) is based on the view
that cancer results after a series of (generally somatic) mutations that knock out
the genetic mechanisms suppressing unregulated cell growth. The chance of these
mutations occurring increases with size and longevity, leading to Peto’s paradox:
why don’t large animals have a higher lifetime incidence of cancer than small ani-
mals? The solution to this paradox is evolution. From an evolutionary perspec-
tive, an increasing frequency of prereproductive cancer deaths results in natural
selection for enhanced cancer suppression. The expected result is a prereproduc-
tive risk of cancer across species that is independent of life history. However,
within species, we still expect cancer risk to increase with size and longevity.
Here, I review the evolutionary model of cancer suppression and some recent
empirical evidence supporting it. Data from humans and domestic dogs confirm
the expected intraspecific association between size and cancer risk, while results
from interspecific comparisons between rodents provide the best evidence to date
of the predicted recruitment of additional cancer suppression mechanisms as spe-
cies become larger or longer lived.
Introduction
In 1971, the ‘war on cancer’ was initiated by Richard Nixon
in the United States, but in reality, the war started with the
evolution of multicellular animals more than half a billion
years earlier. Cancer is a disease unique to multicellular
animals and occurs when a tumour resulting from unregu-
lated cell division invades other tissues. Cancer is not a
problem for plants because the cell wall limits all forms of
cell migration and hence prevents tumour cells from
spreading (Michod 1996; Doonan and Sablowski 2010).
At first sight, cancer appears to be an evolutionary para-
dox: the somatic cells of a cancer are initially genetically
identical to all the other cells of the individual, so the theory
of kin selection (Hamilton 1964) predicts that the best evo-
lutionary strategy is for all somatic cells to co-operate for the
benefit of the germ line. However, there remains an inevita-
ble conflict between the cellular level and the individual level
that drives the occurrence of cancer (Michod 1996; Nunney
1999a). Conflict arises in this apparently benign scenario
because of the general expectation that, although kin selec-
tion promotes cooperation over the long term when related-
ness is high, cooperation is successful only if antisocial
cheating can be prevented (Maynard Smith 1964). This
result applies to the evolution of any organized social struc-
ture that depends upon the collaboration of many lower
level units, each capable of independent replication. In the
context of a multicellular animal, this conflict arises because
a single cell can derive short-term success from its clonal
proliferation within the individual, a success guaranteed
given the abundance of resources available to a selfish cell
surrounded by altruistic brethren. The result is cancer, a cel-
lular strategy that is successful in the short term even though
it ultimately dooms any chance of genetic transmission to
future generations by killing the parent organism. For multi-
cellularity to be successful, such antisocial acts had to be
inhibited by suppression and/or policing (see Maynard
Smith and Szathma´ry 1995; Michod 1999).
Inhibiting cancer is a complex evolutionary problem
because natural selection generally acts most effectively at
the shortest timescale. For this reason, the antisocial
somatic cells that create a cancer by maximizing their own
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short-term reproductive success are very difficult to stop. A
population of cancer cells rapidly accumulates genetic vari-
ation and consequently substantial evolutionary potential
to avoid the body’s defences. At the same timescale, the
body has no evolutionary options. Once a cancer has been
initiated, pre-existing policing mechanisms (e.g. the
immune system) are the only defence, while pre-existing
suppression mechanisms (e.g. tumour suppressor genes)
act earlier, reducing the chance of a cancer ever arising.
Developing these defences in advance requires that selec-
tion must operate at the longer timescale of the individual.
This can be achieved through lineage selection (Nunney
1999a,b), a form of selection that promotes the stability of
a social unit by favouring genetic mechanisms that suppress
or police antisocial activity. In doing so, lineage selection
can be effective in reversing the evolutionary advantage of
short-term replicators. It requires that the social structures
are discrete (i.e. no immigration of new unrelated replica-
tors) and long-lived (relative to the generation time of the
replicators). These conditions are satisfied for the case of
an individual (the social structure) made up of cells (repli-
cators), so we expect mechanisms of cancer suppression
(preventing cancer cells arising) or policing (eliminating
cancer cells once they arise) to be favoured whenever the
occurrence of cancer significantly reduces the average indi-
vidual fitness in the population.
But has not the evolutionary conflict between individuals
and their cells been resolved? There has been plenty of time
since the origin of multicellular animal for lineage selection
to operate, and cancer is a relatively rare disease, except in
individuals of postreproductive age, a pattern consistent
with successful selection. However, this static view of can-
cer suppression overlooks a major problem that was articu-
lated by Peto (1977) and named ‘Peto’s paradox’ (Nunney
1999a). Peto (1977) observed that, because cancer is driven
primarily by somatic mutation, large long-lived humans
should have a much higher incidence of somatic mutations
and hence of cancer than small short-lived mice, but they
do not. Specifically, he noted that ‘a man has 1000 times as
many cells as a mouse…. and we usually live at least 30
times as long as mice…. However, it seems that, in the
wild, the probabilities of carcinoma induction in mice and
in men are not vastly different. Are our stem cells really,
then, 1 billion or 1 trillion times more “cancer proof” than
murine stem cells? This is biologically pretty implausible; if
human DNA is no more resistant to mutagenesis in vitro
than mouse DNA, why don’t we all die of notable carcino-
mas at an early age? Presumably some concomitant of our
evolved ability to grow big and to live for three score years
and ten is involved’ (pp. 1413–1414).
Peto (1977) recognized that some change associated with
evolving larger size and greater longevity had to be involved
in keeping human cancer rates down, and presumed that it
was a fortuitous correlated response of size and longevity
changes. A number of such correlated responses have been
proposed (reviewed by Caulin and Maley 2011); however, a
major problemwith these hypotheses is the lack of any expla-
nation of why a fortuitous response to increased body size
and/or longevity would alter the rate of cancer per cell in such
a way that the overall incidence of cancer, scaled by lifespan,
would stay relatively constant. For example, the (relative) age
distribution of cancers in mice and humans is remarkably
similar (Rangarajan and Weinberg 2003), despite their large
difference in weight and longevity noted by Peto (1977).
A more plausible hypothesis is that whenever a cancer
results in a significant loss of fitness in a population, then
lineage selection will favour the spread of any variant that
lowers the incidence of that cancer (Nunney 1999a). The
result is a simple evolutionary solution to Peto’s paradox
that as specific tissues of a species become more susceptible
to cancer due to increasing size or longevity, the resulting
lowered fitness drives, via selection, the recruitment of
additional cancer suppression mechanisms. Nunney
(1999a) argued that such responses would generally be tis-
sue-specific, directed at the cancer causing the greatest fit-
ness loss. He developed a model to predict the relationship
between the number of genes recruited to suppress cancer
and the size and/or longevity of the source tissue.
Nunney (1999a) modelled cancer suppression based on
the action of tumour suppressor genes and (proto)oncoge-
nes; however, other mechanisms have been suggested as
potential targets for resolving the paradox. Peto (1977)
considered the possibility of DNA repair, but thought it
unlikely to be important given the scale of the problem;
however, modelling shows that a relatively small decrease
in the somatic mutation rate can have a large effect if sup-
pression is multigenic (Nunney 1999a). Cairns (1975) rec-
ognized the power of somatic mutation in driving cancer
in a large rapidly dividing tissue such as the lining of the
gut and proposed a number of potential changes that could
evolve to reduce this effect, including having a limited
number of localized stem cells with asymmetric division.
Recently, DeGregori (2011) has revisited this idea and pro-
posed that increased energy allocation in stem cells in
longer lived and/or larger organisms may limit the accu-
mulation of mutations, although no mechanism was speci-
fied. Other possibilities that have been proposed include
telomere shortening (Nunney 2003), a possibility that now
has strong support (Seluanov et al. 2007, 2008), as does
increased cellular contact inhibition (Seluanov et al. 2009).
These mechanisms and others were recently reviewed by
Caulin and Maley (2011).
Cancer suppression involves two (sometimes overlap-
ping) components. First, there are the genes directly
involved in preventing unregulated cell division (the ‘gate-
keepers’ of Kinzler and Vogelstein 1997). But these controls
© 2012 The Author. Published by Blackwell Publishing Ltd 6 (2013) 11–1912
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can be undermined by inherited and/or somatic mutations.
This mutation-induced loss of regulation drives the first
stages of cancer development: multistage carcinogenesis
(see Weiss 2004). The frequency of inherited mutations is
determined by a process of multigenic mutation-selection
balance (Nunney 2003), a population-level phenomenon
not controlled by individual genotypes; however, somatic
mutation is controlled at the individual level. Minimizing
somatic mutation requires a second group of genes (the
‘caretakers’; Kinzler and Vogelstein 1997) and involves
error-free DNA replication, effective DNA repair, and the
maintenance of appropriate epigenetic patterning (Sarkies
and Sale 2012) and chromosomal structure (Stoler et al.
1999). Classified in either camp are some additional very
important anticancer mechanisms such as the induction of
apoptosis following DNA damage, a process typically
involving what is arguably the most important cancer-con-
trolling gene, p53 (Levine and Oren 2009), and the erosion
of telomeres due to the loss of telomerase activity (Garcia
et al. 2007). If suppression fails, there is a final suite of can-
cer defences, the policing mechanisms, which are processes
acting at a level higher than the single cell that can inhibit
tumour progression. These include, most notably, the
action of the immune system, as seen in the increased inci-
dence of some cancers in immunosuppressed individuals
(Boshoff and Weiss 2002), but also includes any role played
by the healthy tissue around the tumour in limiting angio-
genesis or other aspects of tumour growth.
Predictions of the evolutionary model
The major predictions of the evolutionary model of cancer
suppression developed by Nunney (1999a) are in essence
very simple: an evolutionary increase in the size and/or lon-
gevity of a species will initially drive up the incidence of
cancers; different cancers will increase in frequency to dif-
ferent degrees; and the cancers leading to a significant loss
of fitness will drive selection to reduce their incidence via
increased suppression. As a result, we expect some general
patterns: that within any given species, the large rapidly
dividing tissues will have more levels of cancer suppression
than small slowly dividing ones; that between species, the
large long-lived taxa will have more levels of suppression in
a given tissue than small short-lived taxa; and that although
the genes recruited to enhance suppression in different tis-
sues and/or different species will be selected from a com-
mon pool of possible candidates, the specific controls
recruited will depend upon the genetic variability available
in the population at that particular moment in time. This
last property of the model has the expected result that the
spectrum of genes regulating different cancers in different
tissues within a species may differ, and across species, tis-
sue-specific suppression will share some similarities due to
common ancestry but will diverge depending upon body
size and longevity changes occurring in their lineages after
divergence.
This basic framework leads to the second set of predic-
tions related to population genetics of mutation-selection
balance (Nunney 2003). A relatively subtle prediction is
that very rare early-onset cancers will be primarily genetic
(familial), while relatively common early-onset cancers will
have a higher sporadic component. This prediction arises
from the model because cancer suppression mechanisms
are assumed to be recruited as discrete packages (e.g. an
additional tumour suppressor gene). As a result, at any
given time, some tissues may be relatively overregulated
(very few sporadic cancers) and others under-regulated (a
much higher frequency of sporadic cancers).
An important and robust prediction of the evolutionary
model is that, although the overall prereproductive inci-
dence of specific cancers is predicted to be independent of
tissue size and turnover rate, postreproductive cancers will
be most common in large rapidly dividing (typically epi-
thelial) tissues (Nunney 2003). This last prediction is sup-
ported by the marked age-related shift in human cancers
towards an increasing proportion of epithelial cancers in
old age compared to younger adults (see DePinho 2000).
Furthermore, this shift is expected to be more pronounced
in larger animals, a prediction supported by the compari-
son of common age-related cancers in humans and mice.
In humans, most are epithelial-origin carcinomas, while
mice tend to develop mesenchymal origin lymphomas and
sarcomas (Rangarajan and Weinberg 2003). Thus, although
we cannot as yet compare the array of mechanisms that are
involved in suppressing epithelial carcinomas to those sup-
pressing lymphomas and sarcomas, this age-related shift
seen in humans is consistent with the expectation that can-
cer suppression in large rapidly dividing epithelial tissues is
the most complex.
Like any scientific model, the evolutionary model of can-
cer suppression needs rigorous testing. To help develop
testable predictions, Nunney (1999a) modelled the accu-
mulation of somatic mutations in the development of can-
cer during two stages of development, growth and stem cell
maintenance, and here, we focus on the stage of postgrowth
maintenance, because he noted that a simple approxima-
tion allows the growth phase to be incorporated into that
model. The formula defining the probability of cancer
when it is driven by the accumulation of M somatic muta-
tions in a tissue of C cells during stem cell maintenance is:
p ¼ 1 1
YM
i¼1
f1 expðð1þ DiÞuiKÞg
" #c
ð1Þ
where K is the number of cell divisions, and for locus i, ui is
the somatic mutation rate and Di = 0 if the locus is
© 2012 The Author. Published by Blackwell Publishing Ltd 6 (2013) 11–19 13
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recessive (e.g. a classic tumour suppressor requiring two
mutational ‘hits’ to remove its suppressive effect) or Di = 1
if the locus is dominant (e.g. an oncogene). For small p
(which is always the case in realistic scenarios), eqn (1) can
be usefully (and very accurately) simplified to:
p ¼ c
YM
i¼1
ð2DiuiKÞ ð2Þ
If we assume that all loci are recessive and have the same
mutation rate, then eqn (1) reduces to:
p ¼ 1 ½1 f1 expðuKÞgM c ð3Þ
This special case of eqn (1) was independently derived by
Calabrese and Shibata (2010), an identity that can be seen
from their article by noting that, because u  1 and k > 1,
then to a very close approximation (1u)K = exp(uK).
By analogy to eqn (2), this equation can be approximated
by:
p ¼ CðuKÞM ð4Þ
To fit these equations to human data on the age-specific
incidence of cancer, we can use any of the eqns (1–4) to
link age (t) and cancer rate (dp/dt), which historically we
can consider equivalent to the death rate. Age can be
explicitly included in these equations by replacing K, the
number of divisions, by (kt), where k is the number of divi-
sions/year, and t is age in years. Thus, using eqn (2), we
have:
In
dp
dt
 
¼ In CM
YM
i¼1
ð2DiuikÞ
" #
þ ðM  1ÞInðtÞ
ð5Þ
Simple multistage models are characterized by this linear
relationship between ln(death rate) and ln(age) with a
slope of M1. For example, in the classic work of Armitage
and Doll (1954), it was assumed that mutations had to
occur in a specific order, but this does not alter the slope of
the relationship. Nordling (1953) used death rate data for
carcinomas in men to verify this linear relationship and
obtained a slope of about 6. The more detailed cancer-spe-
cific analysis of Armitage and Doll (1954) provided addi-
tional support for a slope of 5–6 for some cancers (of the
oesophagus, stomach, colon, rectum and pancreas), consis-
tent with M = 6–7 mutations. Their estimates define the
upper limits proposed for M.
At the lower extreme of M, Knudson (1971) proposed
the two-hit model for retinoblastoma (i.e. control by the
single tumour suppressor Rb). Retinoblastoma is a disease
of early childhood that originates in the growing retina.
The two-hit model (where M = 2) accurately accounts for
the incidence of this disease (Hethcote and Knudson 1978),
and Nunney (1999a) showed that the incidence of familial
and sporadic forms could be accurately predicted from a
variant of eqn (1) applicable to growing tissue. This equa-
tion shows that control by a single tumour suppressor gene
provides adequate cancer suppression for tissues smaller
than about 107 cells (i.e. a few times larger than the tiny
embryonic retina) provided it does not exhibit significant
postgrowth division. The severe constraint on size and divi-
sion strongly suggests that retinoblastoma is the only
human cancer controlled by two-hit suppression (Nunney
2003).
The expected relationship between tissue size, somatic
mutation rate and the level of suppression expected to
evolve was shown in Nunney (1999a) for tissues where
early-onset cancers arise during growth and for those tis-
sues that divide continuously throughout life. A notable
feature of these predictions is that the number of tumour
suppressors (or equivalent) is not expected to be large,
plausibly ranging from about 1 to 5 tumour suppressors
(i.e. 2–10 mutational steps in a multistage model),
although the occurrence of significant clonal expansion
(see next paragraph) could raise the upper limit. In any
event, these predictions are important because they
suggest that cancer suppression is not a quantitative trait
controlled by many independent loci of small effect. Thus,
although it is not typically a simple trait controlled by just
one gene, a change in the level of cancer suppression is
expected to be a discrete change rather than part of a
smooth continuum. This has important consequences for
understanding the population genetics of cancer suppres-
sion (Nunney 2003).
The models of Armitage and Doll (1954) and Nunney
(1999a) assume that cancer is a threshold event occurring
after M mutations have accumulated in a cell. In general
(but perhaps excluding retinoblastoma), it is probable that
some clonal expansion (i.e. local tumour development) fol-
lows some or all of the mutational steps leading to cancer.
Nunney (1999a) emphasized that such expansion can be
approximated in the basic model (1) by increasing the
mutation rates to match the effect of clonal expansion (e.g.
increasing 1 cell to 100 cells increases the likelihood of all
subsequent mutations by 100 fold). More explicit model-
ling of this process can take a variety of approaches. For
example, Leubeck and Moolgavkar (2002) examined the
incidence of colorectal cancer using a model in which clo-
nal expansion only occurred late in the mutational progres-
sion but on a scale that substantially increased the
probability of a final cancer-causing mutation, whereas
Beerwinkel et al. (2007) assumed that each mutation in
their multistage model resulted in a small increase in prolif-
erative fitness. In any event, it is clear that precancerous
proliferation of mutated cells can be an important factor in
driving the later development of cancer; Brash (1997)
© 2012 The Author. Published by Blackwell Publishing Ltd 6 (2013) 11–1914
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emphasized this point with his suggestion that proliferation
of surviving but mutated cells after the local death of skin
cells following UV damage may be a factor in increasing
the risk of skin cancer many years later.
Human height and cancer
The evolutionary model of cancer suppression proposed by
Nunney (1999a) predicts that natural selection will elimi-
nate the association between the size of the species and can-
cer incidence. However, this adaptive process does not alter
the size/cancer association within a species. Hence, one of
the critical predictions of the model is an intra-specific
relationship between increasing size and increasing cancer
risk. Human size (as measured by height) varies consider-
ably due to a combination of genetic and environmental
factors. In mammals, such developmental differences typi-
cally reflect a difference in cell number (see Raff 1996; Lui
and Baron 2011); hence, we expect tall individuals to have
a higher cancer risk by virtue of their greater cell number,
whereas weight added later in life as adipose tissue is gener-
ally related to increased cell size. Prior to the 1980s, most
research related to human size focused on body weight,
and results were somewhat contradictory; however, by the
end of the decade, support for the possibility that height
was a universal risk factor in human cancers had grown. At
that time, Albanes and Winick (1988) proposed that within
a species, the cancer risk depended on the number of cells
and their rate of division, which are, of course, the proper-
ties modelled in eqns (1–4). This proposal was empirical:
Albanes et al. (1988) found that height significantly
increased overall cancer risk, and Albanes and Taylor
(1990) presented evidence of a height effect in increasing
the risk for a range of cancers. Specifically, they found sig-
nificant effects for CNS, bladder and pancreatic cancers in
both sexes, prostate, lung and colon cancers in men, and
ovarian, uterine, rectal and breast cancers in women.
Twenty years later, these initial conclusions are much more
strongly supported as data from an increasing number of
large studies have become available. In a meta-analysis of
overall cancer risk using 11 large studies, Green et al.
(2011) estimated a relative risk (RR) per 10 cm of height at
1.10 for men and 1.14 for women. They also examined the
RR for specific cancers within the data from the Million
Women study. Risk increased significantly for 10 of the 17
cancer categories identified, with only one showing a (non-
significant) decrease with height (mouth/pharynx, 0.94).
The three cancer categories with the highest RR were mela-
noma (1.32), kidney (1.29) and leukaemia (1.26).
There can be no doubt that tall humans are at a greater
overall risk of cancer and that this risk is independent of
the effects of obesity (as measured by BMI). For example,
ovarian cancer risk increases with both height and BMI
(Beral et al. 2012), while studies of receptor-positive breast
cancer (John et al. 2010) and testicular cancer (Lerro et al.
2010) both showed a positive height relationship but a neg-
ative BMI effect.
Given such compelling evidence linking height and can-
cer risk in humans, we need to consider whether or not the
effect observed is consistent with the general multistage
model as represented by eqn (2). Specifically, we need to
ask two questions. First, given the expected differences in
cancer suppression between tissues discussed earlier, is the
observation that the increased risk with height is very simi-
lar across very different types of cancer consistent with the
model [as represented by eqn (2)]; and second, is the mag-
nitude of the RR increase in overall cancer risk also consis-
tent with the model? To examine these questions, we have
to express RR in terms of the model: the RR of a 10 cm
increase in height is p(cancer|height (h + 5)cm)/p(cancer|
height (h5) cm). It can be seen from eqn (2) that these
two probabilities are identical except for the value of C,
leading to the simple relationship:
RR ¼ Ctall
Cshort
ð6Þ
This relationship allows us to immediately answer the
first question: the relative risk due to height is predicted to
be independent of tissue type, at least in terms of the
parameters critical to the likelihood of cancer: absolute size
(C), rate of cell division (K), somatic mutation rate (ui)
and the number (M) and nature (Di) of the genes involved
in cancer suppression. However, some variation is expected
because of varying allometric relationships among different
organs, that is, variation across tissues in how cell number
(C) scales with overall height. Regarding the second ques-
tion concerning the magnitude of the effect, eqn (6) pre-
dicts that the RR values for general cancer risk associated
with increased height directly reflect increases in cell num-
ber. On the basis of the Green et al. (2011) estimates, a 10-
cm increase in height increases the overall risk of cancer by
about 14% for women and 10% for men. A simple test of
eqn (6) is whether or not these estimates lead to plausible
values for human height. Assuming an exponent linking
weight and height of 2 (the same exponent used in estimat-
ing the body mass index), these numbers suggest that a 10-
cm increase in height represents roughly a 6.8% increase in
height in women and a 4.9% increase in men, which pre-
dicts the average height of the two sexes to be 147 cm (4′
10″) and 204cm (6′ 8′). These are not very satisfactory;
however, recent estimates of the appropriate exponential
scaling for women and men are 2.17 and 1.78, respectively,
(Heymsfield et al. 2007) leading to much more reasonable
heights of 161 cm (5′ 3″) and 182 (6′ 0″).
In summary, humans show a consistent increase in the
risk of nearly all cancer types with increasing height, and the
© 2012 The Author. Published by Blackwell Publishing Ltd 6 (2013) 11–19 15
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magnitude of this effect is consistent with what is predicted
from a simple multistage model, that is, it is independent of
tissue type and of a magnitude consistent with expectation.
Body size and cancer risk in nonhumans
Artificial selection in domestic dogs has resulted in dra-
matic changes in body size. The high incidence of osteosar-
coma in large dogs (see Withrow et al. 1991) has been cited
as evidence supporting the basic tenet of the evolutionary
model that larger size leads to a higher incidence of cancer
(Leroi et al. 2003). The increase is dramatic, with more
than a 150-fold increase in dogs weighing over 35 kg
(Tjalma 1966). The increase may be directly related to the
change in cell number; however, it can also be argued that
osteosarcoma represents a special case linked to a pathol-
ogy of the extended growth trajectory characteristic of large
breeds (Withrow et al. 1991). For this reason, we need to
examine whether or not there is an increase in the overall
risk of cancer in large dogs. Addressing this question faces
two important complications. First, it is possible that artifi-
cial selection for large size has already resulted in natural
selection for increased cancer suppression. Dogs succumb-
ing to early-onset cancer do not breed so that there is cer-
tainly the potential for additional cancer suppression to be
favoured; however, on balance, we would expect that there
has been too little time for natural selection to counteract
the effects of larger size (Caulin and Maley 2011). Second,
there is the complication of longevity. Large dog breeds are
substantially shorter lived than small dog breeds (Michell
1999). This relationship is an ‘among breeds’ effect that
does not hold within breeds (Galis et al. 2007) and hence
appears to be a correlated response to size selection. As a
result, comparing the lifetime cancer incidence of a breed
close to its ancestral size (about 35 kg) to one that has been
selected for a larger body size (e.g. 60 kg) is confounded by
the difference in their lifespan. The decreased lifespan of
large dogs is predicted to decrease the incidence of cancer
and could easily mask a substantial increase in cancer risk
due to their increased body size. The average sized breeds
would typically have an expected life of around 11 years,
while the larger ones live on average 2 years less (based on
data from Greer et al. 2007). Using eqn (2) to define the
RR for lifetime cancer of large dogs, we have:
RR ¼ Clarge
Caverage
tlarge
taverage
 M
ð7Þ
where C reflects size (weight) differences, and t reflects dif-
ferences in lifespan. Substituting the size and lifespan for
large and average dogs withM = 3 gives an RR of 0.94, that
is, the lifetime cancer risk of the larger dog is less as a result
of their shorter lifespan. This problem could be avoided by
comparing cancer incidence up to a fixed age close to the
maximum age for the large dogs, but substantially below
the maximum for the smaller dogs, for example at 9 years;
however, these data are not readily available.
The relationship between size and cancer susceptibility
in large dogs is masked because their proportional size
gain is small when compared to the reduction in their lon-
gevity raised to the power M (see eqn 7). On the other
hand, the proportional decrease in size seen in the smallest
breeds of dog is substantial and can be expected to swamp
the effect of their increased longevity. We can therefore
predict that small dogs should exhibit a substantial decline
in their lifetime incidence of cancer even though they have
an extended lifespan. This reduction occurs because they
are predicted to have more effective cancer suppression
than is needed for their size and longevity, that is, they are
overregulated. Under natural conditions, if a species is
selected for smaller size, then this selection would be
expected to result in the loss of excess regulation, either
due to the fitness effects of the cost of overregulation or
due to genetic drift resulting in some loss of function
mutations becoming more common; however, these fac-
tors are unlikely to be of importance in small dog breeds
given their short evolutionary history. Thus, a small dog
of 5 kg, with a lifespan of about 13.5 years, has an RR
(compared to the average sized dog) of 0.26 (for M = 3)
and 0.40 (for M = 5). This prediction of a marked decline
in cancer risk in small breeds is borne out in the analysis
of Fleming et al. (2011). They analysed data linking the
cause of death in a range of dog breeds to the breed
weight. Their results show a sharp drop off in death due
to cancer below 30–40 kg with a flat, slightly declining,
relationship of cancer to weight above that range (Fig. 1).
The data from breeds of domestic dogs shown in Fig. 1,
like the data from humans, are consistent with a critical
prediction of the evolutionary model that an increase in
size will increase cancer risk and hence result in selection
Figure 1 The frequency of death due to cancer in 82 breeds of domes-
tic dog classified by their standard weight. Frequency is plotted on an
arcsin (square root) scale that was used to fit a smoothed curve
(Redrawn from Fleming et al. 2011).
© 2012 The Author. Published by Blackwell Publishing Ltd 6 (2013) 11–1916
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for increased cancer suppression. The second critical pre-
diction is that selection leading to a significant change in
the size of species within a clade will result in predicable
interspecific differences in cancer suppression.
One source of evidence on interspecific differences is in
the comparison between human and mouse cells. It has
long been known that mouse cells are sometimes easier to
transform than human cells, and Rangarajan et al. (2004)
demonstrated that, while just two pathways (involving p53
and Raf) need to be perturbed to immortalize mouse fibro-
blasts, an additional four pathways are involved (pRb,
PP2A, telomerase and Ral-GEFs) for human fibroblasts.
However, the most compelling data on interspecific dif-
ferences come from the comparative work of Seluanov
et al. (2007, 2008, 2009) on rodents. Just as domestic dogs
are ideal for studying intraspecific size variation, the rodent
clade is ideal for studying interspecific variation in both
size and longevity. Seluanov et al. (2007) examined one
mechanism of cancer suppression, the repression of telo-
merase activity, in 15 species of rodent. Analysis of a range
of somatic tissues showed that the largest rodents, capybara
and beaver, showed a near complete repression of telomer-
ase activity, while all small rodents showed high levels of
telomerase activity. Given that the capybara and beaver are
very distantly related, their telomerase suppression must
have evolved independently.
The results of Seluanov et al. (2007) were consistent with
an increase in body size leading to increased cancer sup-
pression via telomerase repression; however, this mecha-
nism showed no correlation with longevity. Seluanov et al.
(2008) confirmed the telomerase results using cultured fi-
broblasts, demonstrating replicative senescence in the cells
of the large rodents. They also showed that, in comparing
short- and long-lived rodents that did not repress telomer-
ase activity, cells growth rate was negatively correlated with
longevity and uncorrelated with body size. They concluded
that the mechanisms acting to suppress cancer in large ver-
sus long-lived rodents were different from the mechanisms
acting in small versus large rodents. Further study of the
very long-lived but small naked mole rat (with a maximum
lifespan of > 28 years and body size of only about 35 gm)
showed that their fibroblasts exhibit an unexpected second
level of contact inhibition, a property that may be a power-
ful aid in cancer suppression (Seluanov et al. 2009). These
results demonstrate precisely what is expected under the
evolutionary model: the recruitment of additional but dif-
ferent mechanisms of cancer suppression in response to
increased body size and increased lifespan.
Discussion
An important medical debate concerns how much of our
cancer is due to our environment, how much is due to
our genotype and how much is just bad luck. Resolving
this debate is important for understanding the occurrence
of cancers in the young, for predicting the incidence of
cancers in our increasingly ageing population, for devel-
oping efficient strategies for detecting the genes that inhi-
bit our cancers and, ultimately, for preventing cancer.
The evolutionary model, especially when combined with
the theory of population genetics (Nunney 2003), can
help us gain insight into what determines the frequency
of different forms of cancer. A cancer is ‘nongenetic’
(sporadic) in origin when the set of cancer-causing muta-
tions are due to somatic mutation alone. Environmental
mutagens can drive this process; however, sometimes our
baseline somatic mutation rate is sufficient. When this
occurs, the cancer has no identifiable genetic or environ-
mental cause and, as such, can be described as arising
from bad luck. An evolutionary perspective clarifies the
reasons why we should expect that sometimes (but only
rarely) early-onset cancer will have no identifiable cause
but that for some late-onset cancers, this lack of causation
can be the rule.
A belief is sometimes expressed that the existence of can-
cer indicates that it must be in some sense beneficial; other-
wise, natural selection would surely have eliminated it (e.g.
Lichtenstein 2005; Garcia-Garcia 2009). In actual fact, even
at the most superficial level, the incidence of cancer is
broadly consistent with the action of natural selection act-
ing against a detrimental pathology: prereproductive cancer
is rare, while the incidence of postreproductive cancer is
much higher. This pattern is expected because late-onset
cancers have little or no effect on individual fitness (not-
withstanding such factors as residual help to independent
offspring and their offspring), and hence, their frequency is
much less subject to the action of natural selection. How-
ever, the evolutionary model makes much more precise
predictions than this. In this article, I have focused on two
such predictions, the expected intraspecific increase in can-
cer risk with size and longevity and the expected absence of
these correlations in interspecific comparisons. Others are
also important. For example, DePinho (2000) considered
that an important goal of cancer biology was to explain the
marked age-related increase in carcinomas in humans. The
evolutionary model predicts exactly this pattern that
late-onset cancers will be predominantly those arising from
tissues requiring the most layers of suppression, that is, epi-
thelial tissues (Nunney 2003). On the other hand, the
occurrence of early-onset cancers is determined primarily
by the frequency of mutant alleles that predispose an indi-
vidual to a given cancer. The frequency of such alleles in a
population is determined by mutation-selection balance,
and another set of predictions can be derived from the
mutation-selection balance expected under multistage
carcinogenesis (Nunney 2003).
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Several reviews over the last 10 years have emphasized
the value of incorporating an evolutionary approach into
the study of cancer (Leroi et al. 2003; Crespi and Summers
2005; Merlo et al. 2006; Greaves 2007; Caulin and Maley
2011). Progress in gaining acceptance of these ideas has
been slow, but this is understandable given the paucity of
comparative data. However, the increasing availability of
genomic and expression data in nonmodel organisms will
aid in testing evolutionary ideas. We need to know how
other animals, and especially very large animals (and of
course whales are always mentioned in this context), sup-
press cancer. However, the work of Seluanov et al. (2009)
on the naked mole rat illustrates how intriguing insights
into potential methods of cancer prevention can be found
in well-designed comparative studies of less spectacular
groups of organisms.
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